3350 Stock Chart & Stats
€3.16
-€0.04(-1.25%)
At close: 4:00 PM EDT
€3.16
-€0.04(-1.25%)
Day’s Range― - ―
52-Week Range€1.46 - €4.26
Previous CloseN/A
Volume0.00
Average Volume (3M)0.00
Market Cap
€236.84M
Enterprise Value€189.64
Total Cash (Recent Filing)€189.98M
Total Debt (Recent Filing)€0.00
Price to Earnings (P/E)―
Beta0.23
Next Earnings
Nov 11, 2026EPS Estimate
-0.19Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-1.12
Shares Outstanding57,009,010
10 Day Avg. Volume0
30 Day Avg. Volume0
Financial Highlights & Ratios
PEG Ratio0.09
Price to Book (P/B)1.10
Price to Sales (P/S)20.96
P/FCF Ratio-1.53
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price Target
€7.07Price Target Upside123.72% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering5
EPS Forecast (FY)-1.06
Revenue Forecast (FY)-€1.30M
Bulls Say, Bears Say
Bulls Say
Minimal LeverageThe absence of meaningful debt reduces fixed financial obligations and supports solvency while the larger equity base provides a capital buffer. This gives Whitehawk flexibility to fund development, although it does not offset ongoing operating losses.
Pipeline Expansion And FundingAdditional financing can support development through upcoming milestones, while expanding the CPT113 ADC platform broadens pipeline potential. Together, these events may improve strategic capacity and provide external validation of the technology.
Governance ContinuityA confirmed board, approved executive compensation framework, and continued independent audit relationship provide organizational stability. This supports consistent oversight and execution as the company manages its development pipeline and financing needs.
Bears Say
No Current RevenueThe absence of trailing revenue indicates that Whitehawk has not yet established a commercial operating base. Without recurring product or partnership revenue, future progress remains dependent on clinical development, approvals, and external funding.
Persistent Large LossesLarge recurring losses show that current operating costs substantially exceed revenue generation. Unless development efforts produce commercially meaningful products or partnerships, the company may continue consuming capital and face pressure to reduce spending.
Heavy Cash Burn And Dilution RiskNegative operating and free cash flow means the business is not self-funding and must rely on financing while advancing its pipeline. Repeated capital raises could increase dilution risk and weaken per-share economics if losses persist.
Whitehawk Therapeutics News
3350 FAQ
What was Whitehawk Therapeutics’s price range in the past 12 months?
Whitehawk Therapeutics lowest stock price was €1.46 and its highest was €4.26 in the past 12 months.
What is Whitehawk Therapeutics’s market cap?
Whitehawk Therapeutics’s market cap is €236.84M.
When is Whitehawk Therapeutics’s upcoming earnings report date?
Whitehawk Therapeutics’s upcoming earnings report date is Nov 11, 2026 which is in 75 days.
How were Whitehawk Therapeutics’s earnings last quarter?
Whitehawk Therapeutics released its earnings results on Aug 06, 2026. The company reported -€0.173 earnings per share for the quarter, beating the consensus estimate of -€0.256 by €0.083.
Is Whitehawk Therapeutics overvalued?
According to Wall Street analysts Whitehawk Therapeutics’s price is currently Undervalued.
Does Whitehawk Therapeutics pay dividends?
Whitehawk Therapeutics does not currently pay dividends.
What is Whitehawk Therapeutics’s EPS estimate?
Whitehawk Therapeutics’s EPS estimate is -0.19.
How many shares outstanding does Whitehawk Therapeutics have?
Whitehawk Therapeutics has 57,009,010 shares outstanding.
What happened to Whitehawk Therapeutics’s price movement after its last earnings report?
Whitehawk Therapeutics reported an EPS of -€0.173 in its last earnings report, beating expectations of -€0.256. Following the earnings report the stock price went down -0.578%.
Which hedge fund is a major shareholder of Whitehawk Therapeutics?
Currently, no hedge funds are holding shares in DE:3350
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Whitehawk Therapeutics Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Technicals
SMA
Positive
20 days / 200 days
Momentum
-26.54%
12-Months-Change
Fundamentals
Return on Equity
―
Trailing 12-Months
Asset Growth
7.28%
Trailing 12-Months
Company Description
Whitehawk Therapeutics
Whitehawk Therapeutics, Inc., a clinical-stage oncology therapeutics company that develops technologies to establish tumor biology for cancer treatments. It provides three next generation antibody drug conjugates (ADC) portfolio to treat cancer. The company was formerly known as Aadi Bioscience, Inc. and changed its name to Whitehawk Therapeutics, Inc. in August 2021. Whitehawk Therapeutics, Inc. was incorporated in 2007 and is headquartered in Morristown, New Jersey.
3350 Stock 12 Month Forecast
Average Price Target
€7.07
▲(123.72% Upside)